tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Genmab’s Promising Future: Buy Rating Backed by Strong R&D and Market Performance
RatingsGenmab’s Promising Future: Buy Rating Backed by Strong R&D and Market Performance
1d ago
GMAB
Genmab reports new data from Phase 1b/2 EPCORE CLL-1 trial
PremiumThe Fly
Genmab reports new data from Phase 1b/2 EPCORE CLL-1 trial
4d ago
GMAB
Genmab price target raised to DKK 2,050 from DKK 1,650 at JPMorgan
PremiumThe Fly
Genmab price target raised to DKK 2,050 from DKK 1,650 at JPMorgan
4d ago
GMAB
Genmab announces data from two trials on epcoritamab-bysp
PremiumThe Fly
Genmab announces data from two trials on epcoritamab-bysp
5d ago
GMAB
Genmab announces primary data from Phase 3 EPCORE FL-1 study
PremiumThe Fly
Genmab announces primary data from Phase 3 EPCORE FL-1 study
5d ago
GMAB
Genmab A/S: Promising Growth Prospects with Strategic Catalysts and Robust Pipeline
PremiumRatingsGenmab A/S: Promising Growth Prospects with Strategic Catalysts and Robust Pipeline
12d ago
GMAB
Genmab’s Growth Potential Boosted by Early FDA Approval of Epkinly for Lymphoma Treatment
Premium
Ratings
Genmab’s Growth Potential Boosted by Early FDA Approval of Epkinly for Lymphoma Treatment
23d ago
GMAB
Genmab announces Epkinly combination approved by FDA for lymphoma
Premium
The Fly
Genmab announces Epkinly combination approved by FDA for lymphoma
24d ago
GMAB
FDA approves Genmab’s Epkinly for follicular lymphoma indications
PremiumThe Fly
FDA approves Genmab’s Epkinly for follicular lymphoma indications
24d ago
GMAB
Genmab management to meet virtually with Truist
PremiumThe Fly
Genmab management to meet virtually with Truist
1M ago
GMAB
Genmab price target raised to $41 from $40 at H.C. Wainwright
PremiumThe Fly
Genmab price target raised to $41 from $40 at H.C. Wainwright
1M ago
GMAB
Genmab’s Strong Financial Performance and Promising Pipeline Reinforce Buy Rating
PremiumRatings
Genmab’s Strong Financial Performance and Promising Pipeline Reinforce Buy Rating
1M ago
GMAB
Genmab reports Q3 operating profit $459M, consensus $370.1M
PremiumThe FlyGenmab reports Q3 operating profit $459M, consensus $370.1M
1M ago
GMAB
Genmab affirms 2025 revenue outlook $3.5B-$3.7B, consensus $3.7B
Premium
The Fly
Genmab affirms 2025 revenue outlook $3.5B-$3.7B, consensus $3.7B
1M ago
GMAB
Genmab’s Promising Colorectal Cancer Treatment Drives Buy Rating
Premium
Ratings
Genmab’s Promising Colorectal Cancer Treatment Drives Buy Rating
2M ago
GMAB
Promising Clinical Developments in Genmab’s Portfolio Reinforce Buy Rating
PremiumRatings
Promising Clinical Developments in Genmab’s Portfolio Reinforce Buy Rating
2M ago
GMAB
Genmab falls -6.5%
PremiumThe Fly
Genmab falls -6.5%
2M ago
GMAB
Genmab’s Oncology Advancements and Strategic Positioning Drive Buy Rating
PremiumRatings
Genmab’s Oncology Advancements and Strategic Positioning Drive Buy Rating
2M ago
GMAB
Genmab announces new data from Phase 1/2 RAINFOL-01 trial
PremiumThe Fly
Genmab announces new data from Phase 1/2 RAINFOL-01 trial
2M ago
GMAB
Genmab’s Strong Market Position and Growth Potential Justify Buy Rating with $40 Price Target
PremiumRatingsGenmab’s Strong Market Position and Growth Potential Justify Buy Rating with $40 Price Target
2M ago
GMAB
Genmab reports net sales of Darzalex for Q3 2025 of $3.67B
Premium
The Fly
Genmab reports net sales of Darzalex for Q3 2025 of $3.67B
2M ago
GMAB
Sell Rating on Genmab A/S: Strategic Moves and Financial Challenges Ahead
Premium
Ratings
Sell Rating on Genmab A/S: Strategic Moves and Financial Challenges Ahead
2M ago
GMAB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >